| GR00057-A-1 |
343930 |
XM_292850 |
LOC343930 |
M-022458-00 |
0.19 |
none |
|
no |
|
Wnt/beta-catenin pathway regulation (1) |
A genome-wide RNAi screen for Wnt/beta-catenin pathway components identifies unexpected roles for TCF transcription factors in cancer. |
Tang et al. |
2008 |
18621708 |
Cell line |
HeLa |
Wnt pathway reporter |
Luminescence |
Human siArray siRNA library |
Genome-wide |
siRNA |
Z-score |
> 4 |
Screen without Wnt3A stimulation. Additional information about secondary screens (Dharmacon and Qiagen libraries). |
GR00057-A-2 |
343930 |
XM_292850 |
LOC343930 |
M-022458-00 |
sp |
none |
|
no |
|
Wnt/beta-catenin pathway regulation (2) |
A genome-wide RNAi screen for Wnt/beta-catenin pathway components identifies unexpected roles for TCF transcription factors in cancer. |
Tang et al. |
2008 |
18621708 |
Cell line |
HeLa |
Wnt pathway reporter |
Luminescence |
Human siArray siRNA library |
Genome-wide |
siRNA |
Complex, SP |
Complex criteria |
Screen with Wnt3A stimulation. Additional information about secondary screens (Dharmacon and Qiagen libraries). |
GR00133-A-1 |
343930 |
343930 |
LOC343930 |
np |
-0.452746 |
none |
|
no |
|
Salmonella enterica subspecies 1 serovar Typhimurium invasion (1) |
RNAi screen of Salmonella invasion shows role of COPI in membrane targeting of cholesterol and Cdc42. |
Misselwitz et al. |
2011 |
21407211 |
Cell line |
HeLa |
Gentamycin protection invasion assay |
Fluorescence |
Druggable genome library V2.0 |
Druggable genes |
siRNA |
log2 median |
Complex criteria |
|
GR00180-A-1 |
343930 |
|
MSGN1 |
PL-50081 |
0.796 |
none |
|
no |
|
Hepatitis C virus replication (1) |
A functional genomic screen identifies cellular cofactors of hepatitis C virus replication. |
Tai et al. |
2009 |
19286138 |
Cell line |
Huh7/Rep-Feo |
HCV replicon RNA copy number |
Luminescence |
siARRAY Human Genome siRNA Library |
Genome-wide |
siRNA |
q-value |
Complex criteria |
|
GR00184-A-1 |
343930 |
XM_292850 |
MSGN1 |
M-022458-00 |
-1.43634057485218 |
none |
|
no |
|
Self-renewal and pluripotency in human embryonic stem cells (1) |
A genome-wide RNAi screen reveals determinants of human embryonic stem cell identity. |
Chia et al. |
2010 |
20953172 |
Cell line |
hESC H1 |
POU5F1 protein expression |
Fluorescence |
SMARTpool siRNA library |
Genome-wide |
siRNA |
Z-score |
< -2 |
|
GR00197-A-1 |
343930 |
343930 |
MSGN1 |
M-022458-00 |
-0.182527996 |
none |
|
no |
|
Human papillomavirus oncogene expression regulation (1) |
Genome-wide siRNA screen identifies SMCX, EP400, and Brd4 as E2-dependent regulators of human papillomavirus oncogene expression. |
Smith et al. |
2010 |
20133580 |
Cell line |
C33A/BE2/18LCR c4 |
HPV18 LCR reporter activity |
Luminescence |
Human siGENOME SMARTpool library |
Genome-wide |
siRNA |
Z-score |
> |
Author-submitted data. Phenotype strength according to Z-scores: weak: 2 - 3; moderate: 3 - 5; strong: > 5 |
GR00232-A-1 |
343930 |
XM_292850 |
MSGN1 |
v2HS_143349 |
-1.18220679733333 |
Increased ionizing radiation sensitivity |
|
no |
|
DNA damage regulation after ionizing radiation (1) |
A genetic screen identifies the Triple T complex required for DNA damage signaling and ATM and ATR stability. |
Hurov et al. |
2010 |
20810650 |
Cell line |
U2OS |
Ionizing radiation sensitivity |
Fluorescence |
pSMP |
Genome-wide |
shRNA |
log2 mean ratio |
< -1 OR > 1 |
The shRNA library is in a MSCV-PURO-based vector (MSCV-PM; Open Biosystems nomenclature is pSMP). The shRNAs with the “V3LHS†identifier were subcloned into the MSCV-PM vector from the pGIPZ vector. Additional information about a secondary screen in H460 cells. |
|
343930 |
|
MSGN1 |
np |
np |
Decreased viability in pancreas lineage |
|
no |
pancreas: no filter, two analyses |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GR00236-A-1 |
343930 |
343930 |
MSGN1 |
M-022458-00 |
1.2575552626889 |
none |
|
no |
|
Homologous recombination DNA double-strand break repair (HR-DSBR) (1) |
A genome-wide homologous recombination screen identifies the RNA-binding protein RBMX as a component of the DNA-damage response. |
Adamson et al. |
2012 |
22344029 |
Cell line |
DR-U2OS |
(HR-DSBR) DR-GFP reporter and DNA content |
Fluorescence |
Human siGENOME siRNA (G-005000-05) |
Genome-wide |
siRNA |
Relative HR ratio |
< ~0.4 OR > 1.88 |
Cutoff values correspond 2 standard deviations from the screen-wide mean |
GR00240-S-1 |
343930 |
XM_292850 |
LOC343930 |
M-022458-00 |
-0.68 |
none |
|
yes |
|
TRAIL-induced apoptosis (1) |
A synthetic lethal screen identifies FAT1 as an antagonist of caspase-8 in extrinsic apoptosis. |
Kranz and Boutros |
2014 |
24442637 |
Cell line |
U251MG |
Viability |
Luminescence |
SMART-pool siRNA |
Genome-wide |
siRNA |
Z-score |
> 4 |
Author-submitted data |
GR00240-S-2 |
343930 |
XM_292850 |
LOC343930 |
M-022458-00 |
0.39 |
none |
|
no |
Z-score -0.3195 |
TRAIL-induced apoptosis (2) |
A synthetic lethal screen identifies FAT1 as an antagonist of caspase-8 in extrinsic apoptosis. |
Kranz and Boutros |
2014 |
24442637 |
Cell line |
U251MG |
Viability (synthetic lethal) |
Luminescence |
SMART-pool siRNA |
Genome-wide |
siRNA |
Differential score |
> 3.6 AND viability Z-score < 4 |
Author-submitted data. Z-scores from viability screen (1) are considered in score interpretation for this screen. |
GR00247-A-1 |
343930 |
|
MSGN1 |
np |
sp |
none |
|
|
rank: 14614 |
Regulation of FOXO1 nuclear localization (1) |
Whole genome siRNA cell-based screen links mitochondria to Akt signaling network through uncoupling of electron transport chain. |
Senapedis et al. |
2011 |
21460183 |
Cell line |
U2OS |
EGFP-FOXO1a protein expression and DNA content |
Fluorescence |
Human Genome library |
Genome-wide |
siRNA |
Complex, sp |
Complex criteria |
|
GR00249-S |
343930 |
343930 |
MSGN1 |
s196093 |
-0.73933 |
none |
|
no |
number of cells compared to control (%): 83.32 |
Vaccinia virus (VACV) infection |
Human genome-wide RNAi screen reveals a role for nuclear pore proteins in poxvirus morphogenesis. |
Sivan et al. |
2013 |
23401514 |
Cell line |
HeLa |
Vaccinia virus VACV IHD-J/GFP protein expression and DNA content |
Fluorescence |
Silencer Select Version 4, siGENOME SMARTpool and OnTargetPlus |
Genome-wide |
siRNA |
Z-score |
> |
Author-submitted data. Primary screen. Decreased viability phenotype if number of cells compared to control < 50 %. |
GR00249-S |
343930 |
343930 |
MSGN1 |
s226335 |
1.93869 |
Increased vaccinia virus (VACV) infection |
|
no |
number of cells compared to control (%): 100.42 |
Vaccinia virus (VACV) infection |
Human genome-wide RNAi screen reveals a role for nuclear pore proteins in poxvirus morphogenesis. |
Sivan et al. |
2013 |
23401514 |
Cell line |
HeLa |
Vaccinia virus VACV IHD-J/GFP protein expression and DNA content |
Fluorescence |
Silencer Select Version 4, siGENOME SMARTpool and OnTargetPlus |
Genome-wide |
siRNA |
Z-score |
> |
Author-submitted data. Primary screen. Decreased viability phenotype if number of cells compared to control < 50 %. |
GR00249-S |
343930 |
343930 |
MSGN1 |
s51034 |
1.30872 |
Increased vaccinia virus (VACV) infection |
|
no |
number of cells compared to control (%): 97.17 |
Vaccinia virus (VACV) infection |
Human genome-wide RNAi screen reveals a role for nuclear pore proteins in poxvirus morphogenesis. |
Sivan et al. |
2013 |
23401514 |
Cell line |
HeLa |
Vaccinia virus VACV IHD-J/GFP protein expression and DNA content |
Fluorescence |
Silencer Select Version 4, siGENOME SMARTpool and OnTargetPlus |
Genome-wide |
siRNA |
Z-score |
> |
Author-submitted data. Primary screen. Decreased viability phenotype if number of cells compared to control < 50 %. |
GR00255-A-1 |
343930 |
343930 |
MSGN1 |
TRCN0000017713, TRCN0000017714, TRCN0000017715, TRCN0000017716, TRCN0000017717 |
0.327391171 |
none |
|
|
|
Negative genetic interactions (1) |
A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. |
Vizeacoumar et al. |
2013 |
24104479 |
Cell line |
HCT116 |
shRNA abundance |
Microarray |
np |
Genome-wide |
shRNA |
differential Gene Activity Ranking Profile (dGARP) |
< -1.0 |
HCT116 BLM-/- and HCT116 BLM+/+ cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) |
GR00255-A-2 |
343930 |
343930 |
MSGN1 |
TRCN0000017713, TRCN0000017714, TRCN0000017715, TRCN0000017716, TRCN0000017717 |
0.359883707 |
none |
|
|
|
Negative genetic interactions (2) |
A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. |
Vizeacoumar et al. |
2013 |
24104479 |
Cell line |
HCT116 |
shRNA abundance |
Microarray |
np |
Genome-wide |
shRNA |
differential Gene Activity Ranking Profile (dGARP) |
< -1.0 |
HCT116 MUS81-/- and HCT116 MUS81+/+ cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) |
GR00255-A-3 |
343930 |
343930 |
MSGN1 |
TRCN0000017713, TRCN0000017714, TRCN0000017715, TRCN0000017716, TRCN0000017717 |
0.428760128 |
none |
|
|
|
Negative genetic interactions (3) |
A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. |
Vizeacoumar et al. |
2013 |
24104479 |
Cell line |
HCT116 |
shRNA abundance |
Microarray |
np |
Genome-wide |
shRNA |
differential Gene Activity Ranking Profile (dGARP) |
< -1.2 |
HCT116 PTEN-/- and HCT116 PTEN+/+ cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) |
GR00255-A-4 |
343930 |
343930 |
MSGN1 |
TRCN0000017713, TRCN0000017714, TRCN0000017715, TRCN0000017716, TRCN0000017717 |
0.618008973 |
none |
|
|
|
Negative genetic interactions (4) |
A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. |
Vizeacoumar et al. |
2013 |
24104479 |
Cell line |
HCT116 |
shRNA abundance |
Microarray |
np |
Genome-wide |
shRNA |
differential Gene Activity Ranking Profile (dGARP) |
< -1.2 |
HCT116 PTTG1-/- and HCT116 PTTG1+/+ cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) |
GR00255-A-5 |
343930 |
343930 |
MSGN1 |
TRCN0000017713, TRCN0000017714, TRCN0000017715, TRCN0000017716, TRCN0000017717 |
0.005079181 |
none |
|
|
|
Negative genetic interactions (5) |
A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities. |
Vizeacoumar et al. |
2013 |
24104479 |
Cell line |
HCT116 |
shRNA abundance |
Microarray |
np |
Genome-wide |
shRNA |
differential Gene Activity Ranking Profile (dGARP) |
< -0.8 |
HCT116 KRASG13D/- and HCT116 KRAS+/- cells used. Cutoff corresponds to p-value < 0.05. Additional information about a secondary screen (genetic interactions with Cetuximab/Erbitux in LIM1215 cells) |
GR00300-A |
343930 |
|
MSGN1 |
TRCN0000017717, TRCN0000017713, TRCN0000017714, TRCN0000017715, TRCN0000017716 |
0 |
none |
|
|
|
Combinatorial effect with RAF inhibitor PLX4720 |
A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. |
Whittaker et al. |
2013 |
23288408 |
Cell line |
A375 |
shRNA abundance |
Sequencing |
TRC |
Genome-wide |
shRNA |
Number of shRNAs ranked Top1000 |
> 2 |
The A375 cell line used here harbours the BRAF V600E mutation and is therefore sensitive to RAF inhibitors. |
GR00313-A |
343930 |
XM_292850, XM_939861 |
MSGN1 |
np |
0.54 |
none |
|
|
|
TNF-alpha pathway regulation |
A Genome-Wide RNA Interference Screen Identifies Caspase 4 as a Factor Required for Tumor Necrosis Factor Alpha Signaling. |
Nickles et al. |
2012 |
22733992 |
Cell line |
HEK293T |
NFkappaB pathway reporter |
Luminescence |
Qiagen |
Genome-wide |
siRNA |
Z-score |
< |
Additional filters were a reduction in firefly luciferase levels by at least 50% compared to the mean of the experiment and a concomitant reduction of renilla luciferase expression of not more than 30%. |
GR00343-S |
343930 |
343930 |
MSGN1 |
TRCN0000017717 |
-2.082499999999998 |
shRNA abundance <= 25% |
|
|
|
Lentiviral shRNA "Achilles Heel" screen |
Inhibition of the mitochondrial protease, ClpP, as a therapeutic strategy for human acute myeloid leukemia |
Cole et al. |
2015 |
26058080 |
Cell line |
K562 |
shRNA abundance |
Fluorescence |
Lentiviral shRNA library |
Genome-wide |
shRNA |
Log2 ratio |
< |
Comparison of day 21 vs. day 0 abundance data |
GR00343-S |
343930 |
343930 |
MSGN1 |
TRCN0000017715 |
0.7499999999999982 |
none |
|
|
|
Lentiviral shRNA "Achilles Heel" screen |
Inhibition of the mitochondrial protease, ClpP, as a therapeutic strategy for human acute myeloid leukemia |
Cole et al. |
2015 |
26058080 |
Cell line |
K562 |
shRNA abundance |
Fluorescence |
Lentiviral shRNA library |
Genome-wide |
shRNA |
Log2 ratio |
< |
Comparison of day 21 vs. day 0 abundance data |
GR00343-S |
343930 |
343930 |
MSGN1 |
TRCN0000017716 |
0.40500000000000114 |
none |
|
|
|
Lentiviral shRNA "Achilles Heel" screen |
Inhibition of the mitochondrial protease, ClpP, as a therapeutic strategy for human acute myeloid leukemia |
Cole et al. |
2015 |
26058080 |
Cell line |
K562 |
shRNA abundance |
Fluorescence |
Lentiviral shRNA library |
Genome-wide |
shRNA |
Log2 ratio |
< |
Comparison of day 21 vs. day 0 abundance data |
GR00343-S |
343930 |
343930 |
MSGN1 |
TRCN0000017714 |
0.45250000000000057 |
none |
|
|
|
Lentiviral shRNA "Achilles Heel" screen |
Inhibition of the mitochondrial protease, ClpP, as a therapeutic strategy for human acute myeloid leukemia |
Cole et al. |
2015 |
26058080 |
Cell line |
K562 |
shRNA abundance |
Fluorescence |
Lentiviral shRNA library |
Genome-wide |
shRNA |
Log2 ratio |
< |
Comparison of day 21 vs. day 0 abundance data |
|
343930 |
|
MSGN1 |
np |
1 |
Resistant to vaccinia virus (VACV-A4L) infection |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
343930 |
343930 |
MSGN1 |
|
0 |
none |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GR00371-A-1 |
343930 |
343930 |
MSGN1 |
|
0.250700414389 |
none |
|
|
Ambion |
Nanog expression in absence of bFGF and TGFbeta |
Deterministic Restriction on Pluripotent State Dissolution by Cell-Cycle Pathways |
Gonzales et al. |
2015 |
26232226 |
Cell line |
NANOG-GFP H1 hESC |
NANOG expression |
Fluorescence |
Dharmacon and Ambion |
Selected genes |
siRNA |
Z-score |
>1,25 OR >1,5 [in at least two replicates] |
Z-score shown is an average of the z-scores from the three replicates performed for each gene. In the "Comment" field, the siRNA library used for each particular gene is noted. |
GR00371-A-2 |
343930 |
MSGN1 |
343930 |
|
-0.474556556858 |
none |
|
|
Ambion |
Nanog expression in presence of TGFbeta inhibitor |
Deterministic Restriction on Pluripotent State Dissolution by Cell-Cycle Pathways |
Gonzales et al. |
2015 |
26232226 |
Cell line |
NANOG-GFP H1 hESC |
NANOG expression |
Fluorescence |
Dharmacon and Ambion |
Selected genes |
siRNA |
Z-score |
>1,25 OR >1,5 [in at least two replicates] |
Z-score shown is an average of the z-scores from the three replicates performed for each gene. In the "Comment" field, the siRNA library used for each particular gene is noted. |
GR00371-A-3 |
343930 |
343930 |
MSGN1 |
|
-0.630156058864 |
none |
|
|
Ambion |
Nanog expression in presence of MEK inhibitor |
Deterministic Restriction on Pluripotent State Dissolution by Cell-Cycle Pathways |
Gonzales et al. |
2015 |
26232226 |
Cell line |
NANOG-GFP H1 hESC |
NANOG expression |
Fluorescence |
Dharmacon and Ambion |
Selected genes |
siRNA |
Z-score |
>1,25 OR >1,5 [in at least two replicates] |
Z-score shown is an average of the z-scores from the three replicates performed for each gene. In the "Comment" field, the siRNA library used for each particular gene is noted. |
GR00371-A-4 |
343930 |
343930 |
MSGN1 |
|
0.243397640011 |
none |
|
|
Ambion |
Nanog expression in presence of PI3K inhibitor |
Deterministic Restriction on Pluripotent State Dissolution by Cell-Cycle Pathways |
Gonzales et al. |
2015 |
26232226 |
Cell line |
NANOG-GFP H1 hESC |
NANOG expression |
Fluorescence |
Dharmacon and Ambion |
Selected genes |
siRNA |
Z-score |
>1,25 OR >1,5 [in at least two replicates] |
Z-score shown is an average of the z-scores from the three replicates performed for each gene. In the "Comment" field, the siRNA library used for each particular gene is noted. |
GR00371-A-5 |
343930 |
343930 |
MSGN1 |
|
-1.18932176954 |
none |
|
|
Ambion |
Nanog expression in presence of retinoic acid |
Deterministic Restriction on Pluripotent State Dissolution by Cell-Cycle Pathways |
Gonzales et al. |
2015 |
26232226 |
Cell line |
NANOG-GFP H1 hESC |
NANOG expression |
Fluorescence |
Dharmacon and Ambion |
Selected genes |
siRNA |
Z-score |
>1,25 OR >1,5 [in at least two replicates] |
Z-score shown is an average of the z-scores from the three replicates performed for each gene. In the "Comment" field, the siRNA library used for each particular gene is noted. |
GR00376-A-1 |
343930 |
343930 |
MSGN1 |
|
0.014236326 |
none |
|
|
|
Mitigators of SS1P-induced immunotoxicity |
Whole-genome RNAi screen highlights components of the endoplasmic reticulum/Golgi as a source of resistance to immunotoxin-mediated cytotoxicity |
Pasetto et al. |
2015 |
25713356 |
Cell line |
KB cells |
Viability |
Luminescence |
Ambion Silencer Select Version 4 |
Genome-wide |
siRNA |
RSA P-value |
<0.001 |
SS1P was applied in a "high dose", ≈EC90, 13 ng/ml. Cutoff was derived from data submitted to Pubchem (ID 1117281). Reagent sequences but no ID |
GR00376-A-2 |
343930 |
343930 |
MSGN1 |
|
0.771819351 |
none |
|
|
|
Sensitizers of SS1P-induced immunotoxicity |
Whole-genome RNAi screen highlights components of the endoplasmic reticulum/Golgi as a source of resistance to immunotoxin-mediated cytotoxicity |
Pasetto et al. |
2015 |
25713356 |
Cell line |
KB cells |
Viability |
Luminescence |
Ambion Silencer Select Version 4 |
Genome-wide |
siRNA |
RSA P-value |
<0.001 |
SS1P was applied in a "low dose", ≈EC30, 3 ng/ml. Cutoff was derived from data submitted to PubChem (ID 1117281). Reagent sequences but no ID |